Theralink Technologies, Inc. (THER)

0.0010 -0.0001 (-9.09%) At close: 03:20PM EDT

Theralink Technologies, Inc.

15000 West 6th Avenue
Suite 400
Golden, CO 80401
United States
888 585 4923
https://www.theralink.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 16

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Faith Zaslavsky	President & CEO	404.55k	N/A	1973
Mr. Andrew Albert Kucharchuk M.B.A.	CFO & Director	222.87k	N/A	1981
Dr. Michael I. Ruxin M.D.	Chief Medical Officer & Director	1.16M	N/A	1946
Mr. Trevor McCartney	VP of Sales Operations & Strategic Partnerships	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States. The company offers patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It also provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. In addition, the company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. The company was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. Theralink Technologies, Inc.is headquartered in Golden, Colorado.

Corporate governance

Theralink Technologies, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.